ArticleGlycobiology2026
The protein sequence modulates terminal GalNAc incorporation during N-glycan biosynthesis.
Article in Glycobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The factors governing protein-specific N-glycosylation remain incompletely understood despite extensive knowledge of the biosynthetic machinery involved in glycan assembly. In particular, the contribution of the protein sequence itself to the final glycosylation pattern has received comparatively little attention. Here, we employed isotope-assisted NMR spectroscopy to investigate the N-glycosylation of the receptor-binding domain of the SARS-CoV-2 spike glycoprotein (RBD-SCoV2) produced in HEK293F cells. Previous analyses revealed the unexpected presence of terminal GalNAc-containing epitopes, including LacdiNAc (LDN), sulfated LacdiNAc (4S-LDN), sialylated LacdiNAc (6Sia-LDN), and fucosylated LacdiNAc (LDNF). Inspired by earlier studies showing that certain β4GalNAc-transferases recognize basic peptide motifs, we generated an RBD variant carrying four substitutions of solvent-exposed basic residues located near the N-glycosylation sites. Comparative NMR analysis demonstrated that the mutant protein exhibits a marked reduction in GalNAc-containing terminal epitopes, accompanied by a corresponding increase in Gal-containing structures. The overall protein fold remained unchanged, indicating that the observed glycosylation differences arise from altered glycan processing rather than major structural perturbations. These findings provide direct evidence that local protein sequence features modulate the incorporation of terminal glycan epitopes during Golgi processing. More broadly, this work highlights the power of quantitative NMR spectroscopy for the structural characterization of glycoproteins and for detecting subtle changes in glycan populations that are directly linked to protein sequence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.